|
Bruce Booth joined Atlas Venture in 2005 as a Principal on the Life Sciences team.
Prior to Atlas Venture, Bruce was a Principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm. He focused on the firm’s private equity activities, ranging from early stage venture capital through late stage buyouts. Prior to joining Caxton Health, he was an Associate Principal at McKinsey & Company, a global strategic management consulting firm, where he focused on R&D productivity, corporate strategy, and business development issues for several major biopharmaceutical companies. While at McKinsey, he also co-led the Firm’s international scholars recruiting efforts.
Bruce works closely with Atlas Venture portfolio companies ARCA Discovery, Archemix, Conxcys, Dynogen, NxStage Medical, Prestwick Pharmaceuticals, Proprius Pharmaceuticals, SGX Pharmaceuticals (NASDAQ: SGXP) and Zafgen. He serves on the Board of Zafgen.
As a British Marshall Scholar, Bruce earned a Doctorate in Molecular Immunology from the Oxford University’s Nuffield Department of Medicine and the Weatherall Institute of Molecular Medicine. His research focused on viral and tumor immune surveillance, and how the immune system responds to intracellular pathogenesis. During his graduate studies at Oxford, he also received the Overseas Research Fellowship and served as junior dean of Trinity College. Prior to graduate studies, he worked on President Clinton’s Domestic Policy Council in the National Office of AIDS Policy. He received a Bachelor of Science degree with highest honors in Biochemistry from the Pennsylvania State University, where he was an Evan Pugh Scholar.
He currently serves on the New York Academy of Medicine Board of Trustees, and is an active member of the Council on Foreign Relations. Bruce has also authored numerous scientific papers and reviews, including several in Nature Reviews Drug Discovery.
Investment Sector : Life Sciences
Portfolio Companies :
ARCA Discovery, Archemix, Dynogen , NxStage, Prestwick Pharmaceuticals, Proprius Pharmaceuticals, SGX Pharmaceuticals
Boards :
Zafgen
In the News:
NxStage Medical to Present at the William Blair Growth Stock Conference on June 21, 2007
Archemix and Takeda to Enter into Collaboration for Discovery and Development of Aptamer Therapeutics
ARCA Discovery Completes $18 Million Equity Financing to Advance Targeted Cardiovascular Therapies and Submit Lead Product for Approval This Year
Archemix and Merck KGaA Sign Strategic Alliance
Archemix Announces Completion of Phase 1 Trial of ARC1779
Archemix Announces Completion of Phase 1 Trial of ARC1779
Dynogen Reports Positive Results in Phase 1B GERD Study
FierceBiotech Names Archemix Corp. as One of the Fierce 15" Biotech Companies of 2007
Clinical Trial Results Suggest Long-Term Treatment Benefit of Tetrabenazine for Chorea Associated with Huntington’s Disease | 